Overview

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection

Status:
Completed
Trial end date:
2017-02-09
Target enrollment:
Participant gender:
Summary
The purpose of this phase 3, multicenter study is to evaluate the efficacy and safety of ABT-493/ABT-530 in Japanese adults with chronic Hepatitis C Virus (HCV)-infected, HCV direct-acting antiviral agent (DAA) treatment-naïve, and DAA treatment-experienced Japanese adult subjects.
Phase:
Phase 3
Details
Lead Sponsor:
AbbVie
Treatments:
Ritonavir